ENB Therapeutics Overview
- Year Founded
-
2015
- Status
-
Private
- Employees
-
6
- Latest Deal Type
-
2ndary - Private
- Investors
-
6
ENB Therapeutics General Information
Description
Developer of small molecule inhibitors designed to overcome resistance towards cancer immunotherapy and reduce tumor growth. The company's inhibitors target the endothelial receptor to reverse the drug resistance that occurs in patients treated with immunotherapy, enabling physicians to reduce tumor growth and prolong survival in a variety of immunotherapy-resistant cancers.
Contact Information
Website
enbpharma.comCorporate Office
- 45-18 Court Square West
- 6th floor, Long Island City
- New York, NY 11101
- United States
Corporate Office
- 45-18 Court Square West
- 6th floor, Long Island City
- New York, NY 11101
- United States
ENB Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Secondary Transaction - Private | 01-Apr-2026 | Completed | Clinical Trials - Phase 1 | |||
| 7. Later Stage VC | 03-Oct-2023 | Completed | Clinical Trials - Phase 1 | |||
| 6. Later Stage VC | 03-Jan-2022 | Completed | Clinical Trials - Phase 1 | |||
| 5. Later Stage VC | 01-Mar-2021 | Completed | Clinical Trials - Phase 1 | |||
| 4. Later Stage VC (Series A) | 27-Feb-2020 | Completed | Clinical Trials - Phase 1 | |||
| 3. Early Stage VC (Series A) | 12-Sep-2018 | Completed | Pre-Clinical Trials | |||
| 2. Angel (individual) | 25-Apr-2017 | $110K | $110K | Completed | Pre-Clinical Trials | |
| 1. Accelerator/Incubator | 25-Apr-2016 | Completed | Pre-Clinical Trials |
ENB Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
ENB Therapeutics Comparisons
Industry
Financing
Details
ENB Therapeutics Competitors (117)
One of ENB Therapeutics’s 117 competitors is Orchard Therapeutics, a Formerly VC-backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Orchard Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| Aro Biotherapeutics | Venture Capital-Backed | Philadelphia, PA | ||||
| Verastem | Formerly VC-backed | Needham, MA | ||||
| Cytokinetics | Formerly VC-backed | South San Francisco, CA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA |
ENB Therapeutics Patents
ENB Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4608447-A1 | Methods for treating cancers associated with etbr activation | Pending | 28-Oct-2022 | ||
| US-20260130999-A1 | Methods for treating cancers associated with etbr activation | Pending | 28-Oct-2022 | ||
| WO-2024092239-A1 | Methods for treating cancers associated with etbr activation | Inactive | 28-Oct-2022 | ||
| US-20200268829-A1 | Methods and compositions for inhibiting metastases of an endothelin b receptor expressing cancer | Inactive | 24-Mar-2020 | ||
| US-20200289495-A1 | Methods of inhibiting endothelin b receptor expressing tumor metastases | Inactive | 24-Mar-2020 | A61K31/4025 |
ENB Therapeutics Signals
ENB Therapeutics Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Avestria Ventures | Venture Capital | Minority | ||
| Alexandria Venture Investments | Venture Capital | Minority | ||
| BioAdvance Capital (Conshohocken) | Venture Capital | Minority | ||
| Remiges Ventures | Venture Capital | Minority | ||
| AJI Capital | Venture Capital | Minority |
ENB Therapeutics FAQs
-
When was ENB Therapeutics founded?
ENB Therapeutics was founded in 2015.
-
Where is ENB Therapeutics headquartered?
ENB Therapeutics is headquartered in New York, NY.
-
What is the size of ENB Therapeutics?
ENB Therapeutics has 6 total employees.
-
What industry is ENB Therapeutics in?
ENB Therapeutics’s primary industry is Drug Discovery.
-
Is ENB Therapeutics a private or public company?
ENB Therapeutics is a Private company.
-
What is ENB Therapeutics’s current revenue?
The current revenue for ENB Therapeutics is .
-
How much funding has ENB Therapeutics raised over time?
ENB Therapeutics has raised $21.1M.
-
Who are ENB Therapeutics’s investors?
Avestria Ventures, Alexandria Venture Investments, BioAdvance Capital (Conshohocken), Remiges Ventures, and AJI Capital are 5 of 6 investors who have invested in ENB Therapeutics.
-
Who are ENB Therapeutics’s competitors?
Orchard Therapeutics, Aro Biotherapeutics, Verastem, Cytokinetics, and Kite Pharma are some of the 117 competitors of ENB Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process